Evidence map›Paper›PMID 39027279›Full record

ArticleChemical science2024

Catalytic asymmetric intramolecular propargylation of cyclopropanols to access the cuparane core.

Yankun Zhao, Hongya Yan, Yulian Zhang, Tao Zhou, Mengxing Tian, Chongzhou Zhang, Shan Yuan, Hanyue Qiu, Ling He, Min Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yankun ZhaoChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.
Hongya YanChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.
Yulian ZhangChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.
Tao ZhouChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.
Mengxing TianChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.
Chongzhou ZhangChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.
Shan YuanChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.
Hanyue QiuChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.
Ling HeChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.ORCID https://orcid.org/0000-0002-7062-6709
Min ZhangChongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University Chongqing 401331 China hanyue.qiu@cqu.edu.cn minzhang@cqu.edu.cn.ORCID https://orcid.org/0000-0002-3851-7836

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The catalytic asymmetric propargylation of enol(ate) intermediates is a well-established method for the synthesis of α-propargyl-substituted carbonyl compounds. However, the propargylation of homo-enol(ate) or its equivalents for the synthesis of β-propargyl-substituted carbonyl compounds remains underdeveloped. A catalytic enantioselective decarboxylative intramolecular propargylation of cyclopropanols has been developed using a PyBox-complexed copper catalyst. This reaction offers an effective approach to assemble a cyclopentanone skeleton bearing an all-carbon quaternary stereogenic center and an adjacent quaternary

Identifiers

PMID39027279
PMCPMC11253112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.